MedTrace Logo

Efficacy and Safety Study of F373280

NCT01831856 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2019-07-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy of F373280 on the maintenance of normal cardiac rhythm after direct electric cardioversion in patients with persistent atrial fibrillation and cardiac failure.

Conditions

Interventions

DRUG

1g of F373280

Oral administration, one capsule each evening with dinner.

DRUG

Placebo

Oral administration, one capsule each evening with dinner.

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Principal Investigators

  • Karim Keddad, MD · PierreFabre Medicamment

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-04-03
Completion
2017-06-21

Countries

  • Czechia
  • Hungary
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01831856 on ClinicalTrials.gov